OneSource Specialty Pharma's Q1 FY 2025-26 Quarter Results

Result Summary

• OneSource Specialty Pharma Ltd reported a 338.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 12.2%.
• Its expenses for the quarter were up by 188.2% QoQ and down 1.3% YoY.
• The net profit decreased 99.5% QoQ and decreased 96.6% YoY.
• The earnings per share (EPS) of OneSource Specialty Pharma Ltd - at - during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

OneSource Specialty Pharma Ltd is a company operating in the pharmaceutical industry, primarily focused on providing specialty pharmaceutical products. The company is known for its role in developing, manufacturing, and distributing a variety of medications that cater to niche therapeutic needs. While specific recent developments are not provided, companies in this sector typically engage in continuous research and development to bring innovative solutions to market. Information on new product launches or strategic partnerships that may have influenced recent financial performance is not available within the provided data.

Revenue

During the first quarter of fiscal year 2026 (Q1FY26), OneSource Specialty Pharma Ltd reported a total income of ₹332.54 crores. This marks a significant QoQ increase of 338.8% compared to ₹75.78 crores in Q4FY25, and a YoY increase of 12.2% compared to ₹296.28 crores in Q1FY25. The substantial QoQ growth indicates a recovery or expansion in the company's revenue-generating activities compared to the previous quarter. The YoY growth, although more modest, suggests a steady increase in revenue over the year. The surge in revenue could be attributed to factors such as increased sales volumes, price adjustments, or the introduction of new products, though specific reasons are not detailed in the data.

Profitability

For Q1FY26, OneSource Specialty Pharma Ltd reported a Profit Before Tax (PBT) of ₹-4.40 crores, which shows a significant improvement from the previous quarter's PBT of ₹-40.17 crores. This reflects an 89.0% reduction in losses on a QoQ basis. Compared to Q1FY25, where the PBT was ₹-46.62 crores, there is a notable 90.6% YoY improvement. The Profit After Tax (PAT) for Q1FY26 was ₹-0.19 crores, indicating a substantial QoQ improvement from ₹-40.17 crores in Q4FY25 and a 96.6% improvement from ₹-5.55 crores in Q1FY25. The tax expense or credits in Q1FY26 were ₹-4.21 crores, showing a decrease from the prior year. Earnings Per Share (EPS) was reported at ₹0.00 for Q1FY26, an improvement from ₹-9.70 in Q4FY25.

Operating Metrics

OneSource Specialty Pharma Ltd's total expenses for Q1FY26 were ₹334.07 crores, representing a QoQ increase of 188.2% from ₹115.93 crores in Q4FY25, and a slight YoY decrease of 1.3% from ₹338.39 crores in Q1FY25. Despite the increase in expenses compared to the previous quarter, the YoY decrease suggests some cost efficiencies or changes in operational strategies over the year. The substantial QoQ increase in both income and expenses indicates a period of high operational activity. However, the data does not provide specific details on the components of these expenses. No P/E ratio, debt-to-equity ratio, or current ratio calculations can be derived from the provided data, as essential balance sheet figures are not included.